Drug Profile
Abrilumab - Amgen/AstraZeneca
Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Ulcerative colitis
Most Recent Events
- 10 Apr 2018 AstraZeneca completes a phase II trial for Ulcerative colitis in Japan (SC) (NCT01959165)
- 10 Apr 2018 Amgen completes a phase II trial for Ulcerative colitis in USA, Canada, Australia, United Kingdom, Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Netherlands, Poland, Norway, Switzerland and Russia (SC) (NCT01694485)
- 10 Apr 2018 Amgen completes a phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)